6,932 Shares in AbbVie Inc. $ABBV Acquired by PICTET BANK & TRUST Ltd

PICTET BANK & TRUST Ltd acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 6,932 shares of the company’s stock, valued at approximately $1,605,000. AbbVie accounts for about 1.9% of PICTET BANK & TRUST Ltd’s holdings, making the stock its 20th biggest position.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in AbbVie during the 2nd quarter valued at $4,288,200,000. Laurel Wealth Advisors LLC lifted its stake in shares of AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of AbbVie by 550.9% in the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after buying an additional 3,666,521 shares in the last quarter. Vanguard Group Inc. grew its holdings in AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new stake in AbbVie during the 2nd quarter valued at approximately $581,817,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $229.26 on Friday. The firm’s fifty day moving average is $226.69 and its 200-day moving average is $213.74. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The firm has a market cap of $405.19 billion, a PE ratio of 173.68, a price-to-earnings-growth ratio of 0.96 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is 496.97%.

Analyst Ratings Changes

ABBV has been the topic of several research reports. Wells Fargo & Company upped their price objective on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Raymond James Financial set a $256.00 price target on AbbVie in a research note on Monday, November 3rd. Guggenheim upped their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Finally, HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and raised their target price for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $245.84.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.